AU2013334664A1 - N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels - Google Patents

N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels Download PDF

Info

Publication number
AU2013334664A1
AU2013334664A1 AU2013334664A AU2013334664A AU2013334664A1 AU 2013334664 A1 AU2013334664 A1 AU 2013334664A1 AU 2013334664 A AU2013334664 A AU 2013334664A AU 2013334664 A AU2013334664 A AU 2013334664A AU 2013334664 A1 AU2013334664 A1 AU 2013334664A1
Authority
AU
Australia
Prior art keywords
indazole
sulfonamide
fluoro
fluoropyridin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013334664A
Other languages
English (en)
Inventor
Michael J. Kelly Iii
Mark E. Layton
Hannah D. G. F. Lehman
Joseph E. Pero
Michael A. Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2013334664A1 publication Critical patent/AU2013334664A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
AU2013334664A 2012-10-26 2013-10-23 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels Abandoned AU2013334664A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719118P 2012-10-26 2012-10-26
US61/719,118 2012-10-26
PCT/US2013/066360 WO2014066491A1 (en) 2012-10-26 2013-10-23 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels

Publications (1)

Publication Number Publication Date
AU2013334664A1 true AU2013334664A1 (en) 2015-05-07

Family

ID=50545213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334664A Abandoned AU2013334664A1 (en) 2012-10-26 2013-10-23 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels

Country Status (10)

Country Link
US (1) US9388179B2 (https=)
EP (1) EP2911663B1 (https=)
JP (1) JP2015535252A (https=)
KR (1) KR20150074123A (https=)
CN (1) CN104869992A (https=)
AU (1) AU2013334664A1 (https=)
BR (1) BR112015008987A2 (https=)
CA (1) CA2891056A1 (https=)
RU (1) RU2015119640A (https=)
WO (1) WO2014066491A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CA2979534A1 (en) * 2015-03-13 2016-09-22 Abbvie Inc. (indazol-4-yl)hexahydropyrrolopyrrolones and method of use
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック, インコーポレイテッド 治療化合物及びその使用方法
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
AU2016370554B2 (en) 2015-12-18 2018-11-29 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
PL3458449T3 (pl) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック, インコーポレイテッド ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
CN107247885B (zh) * 2017-07-06 2020-07-03 中国水产科学研究院黄海水产研究所 一种电压-门控钠离子通道的结构预测方法
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
WO2020192553A1 (zh) * 2019-03-22 2020-10-01 上海海雁医药科技有限公司 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途
US12552797B2 (en) 2019-11-27 2026-02-17 Praxis Precision Medicines, Inc. Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine
AR128499A1 (es) 2022-02-14 2024-05-15 Arase Therapeutics Inc Inhibidores de parg
TW202345811A (zh) * 2022-03-31 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 吲唑類化合物、其製備方法及其在醫藥上的應用
MX2024013240A (es) 2022-04-26 2024-12-06 Praxis Prec Medicines Inc Tratamiento de trastornos neurologicos
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705185A (en) 1969-04-14 1972-12-05 Minnesota Mining & Mfg N-aroyl sulfonamides
US4136256A (en) 1977-09-27 1979-01-23 American Cyanamid Company 4-(monoalkylamino)benzoic acid imidates
US4309553A (en) 1977-09-27 1982-01-05 American Cyanamid Company Aldehydes and ketones containing a 4-(monoalkylamino)-benzoyl substituent
US4242273A (en) 1977-09-27 1980-12-30 American Cyanamid Company 4-(Monoalkylamino)benzoic acid amides and imidates
US4272546A (en) 1977-12-19 1981-06-09 American Cyanamid Company Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids
US4254138A (en) 1977-12-19 1981-03-03 American Cyanamid Company Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids
US4205085A (en) 1978-03-09 1980-05-27 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds
US4243609A (en) 1978-02-02 1981-01-06 American Cyanamid Company Ring-fluorinated 4-(hexadecyl-amino) N-substituted benzamide compounds
US4245097A (en) 1978-02-27 1981-01-13 American Cyanamid Company 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents
US4230878A (en) 1978-03-08 1980-10-28 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives
US4230628A (en) 1978-04-12 1980-10-28 American Cyanamid Company 4-[(Carboxyl- and sulfamyl-substituted alkyl)-amino] benzoic acids and analogs
US4211783A (en) 1978-03-20 1980-07-08 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds
US4227014A (en) 1978-02-27 1980-10-07 American Cyanamid Company 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof
US4305959A (en) 1978-03-09 1981-12-15 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4310545A (en) 1978-03-09 1982-01-12 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds
US4318914A (en) 1978-03-09 1982-03-09 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4485105A (en) 1978-10-12 1984-11-27 American Cyanamid Company Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides
DK471479A (da) 1978-12-13 1980-06-14 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US4670421A (en) 1982-07-12 1987-06-02 American Cyanamid Company Antiatherosclerotic silanes
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
KR20080015102A (ko) * 2005-05-10 2008-02-18 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
CA2693588C (en) * 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
EP2355659A4 (en) * 2008-10-23 2012-10-10 Merck Sharp & Dohme Fused Hetereocyclic M1 Receptor Positive Allosmatic Modulators
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012064984A1 (en) 2010-11-10 2012-05-18 Datalogic Scanning, Inc. Adaptive data reader and method of operating
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors

Also Published As

Publication number Publication date
WO2014066491A1 (en) 2014-05-01
EP2911663B1 (en) 2020-03-18
EP2911663A4 (en) 2016-04-13
CN104869992A (zh) 2015-08-26
EP2911663A1 (en) 2015-09-02
JP2015535252A (ja) 2015-12-10
CA2891056A1 (en) 2014-05-01
US20150284389A1 (en) 2015-10-08
BR112015008987A2 (pt) 2017-07-04
KR20150074123A (ko) 2015-07-01
US9388179B2 (en) 2016-07-12
RU2015119640A (ru) 2016-12-20

Similar Documents

Publication Publication Date Title
EP2911663B1 (en) N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
US9624208B2 (en) Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
CN113382991B (zh) 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
EP2770995B1 (en) Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
EP3268006B1 (en) Pyrrolotriazine inhibitors of irak4 activity
EP3074402B1 (en) Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
JP2025120943A (ja) 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類
TWI577674B (zh) 二氫-苯并-及二氫-吡啶并-衍生物
TWI534145B (zh) 四氫吡啶并嘧啶衍生物
EP3541373B1 (en) Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
TW201534598A (zh) 經取代之喹唑啉-4-酮衍生物
TWI822713B (zh) 適用於治療或預防與其相關之病症之β-3腎上腺素受體的調節劑
BR112016008276B1 (pt) derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
EP3307067B1 (en) Aminopyrazine compounds with a2a antagonist properties
CN104870451B (zh) 二氢‑吡啶并噁嗪衍生物的固体形式
EP3983414B1 (en) Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels
TW202304906A (zh) 高活性hpk1激酶抑制劑
CN109415371B (zh) 一种2-酰氨基噻唑衍生物及其制备方法与用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application